Spinverse strengthens its EU project portfolio in Life Sciences with PeptiCaps

The PeptiCaps project develops a novel nanotechnology for the delivery of specific active ingredients in skin care application.

Safe and efficient nanocapsules releasing active ingredients in response to certain skin conditions, such as allergic contact dermatitis, skin irritations, sun damage and pigmentation problems, are set to become reality in the PeptiCaps project.

The “smart” nanocapsules developed in the project will be designed to respond to changes in pH and enzyme secretion in the affected skin area, delivering the active ingredients where and when the skin conditions occur. Their effectiveness will be validated by comparing them with equivalent products that do not respond to stimuli.

Given the growing public and academic concern regarding the safety, health risks and ecotoxicity of engineered nanomaterials, the project will also study these aspects of the products that are developed in accordance with the guidelines set by the OECD.

This EU-funded project, coordinated by Spanish IK4-CIDETEC, combines the expertise of nine European organisations from five different countries, 4 companies and 5 research centers. Spinverse already participated in the preparation of the proposal, helping in ensuring the funding of €3,85 million for the 3-year project with excellent evaluation scores. During the project itself, Spinverse will take part by creating and developing the business plan for the novel nanocapsules, and supporting the project’s exploitation and dissemination efforts.

With Pepticaps, Spinverse strenghtens further its expertise in Life Sciences

Spinverse has already broadened its portfolio of projects within health and biotech sectors as demonstrated by its recent examples of successful projects in the field of biotech and health/pharma sectors:

• NanoPilot, where Spinverse helped in securing €6.3 million in EU funding for a pilot plant to produce polymer-based nano-pharmaceuticals. During the 4-year project, Spinverse creates the business plan for the plant.
• IP4Plasma enables industrial innovations based on EU IP assets in plasma technology. The project aims at creating a highly sensitive tuberculosis test to allow diagnosis within minutes at a cost as low as €1 per test, as well as advanced wound dressings. After successfully managing the preparation of the proposal, Spinverse coordinates the project and develops the commercialisation strategy of the technology.
• APEX project is a MetGen project in which Spinverse provided support in successfully applying for Horizon 2020 SME instrument phase 2 funding. The project aims at the scale-up from pilot to industrial scale production of MetZyme®, an enzyme solution developed by MetGen, and the improvement of the cost-efficiency of the industrial enzyme development.
• CLEEN/FIBIC BEST. With the expertise in building and managing PPPs, Spinverse helped launch BEST (Sustainable Bioenergy Solutions for Tomorrow) to enable a stronger and more competitive Finnish bioenergy ecosystem.

In order to serve even better its clients in these sectors, Spinverse has also strengthened the number of its professionals during the past 6 months with Riikka Paasikivi and Catherine Bounsaythip joining Spinverse, bringing with them their extensive network and experience in research and business development within health, bio and pharma industries.